Ipamorelin: The Peptides Came First, Then the Receptor, Then the Hormone
GHRP-6 was reported in 1984, its receptor found in 1996 and the body's own hormone for it in 1999. The hormone that came last reclassified the whole family.
Shop by category
Growth Hormone Axis ResearchRegeneration ResearchPeptide BioregulatorsCognitive & Neuropeptide ResearchMetabolic & Cellular ResearchGLP-1 & Incretin ResearchMelanocortin & Endocrine ResearchDermal Peptide ResearchImmune & Thymic ResearchPeptide BlendsLab SuppliesResearch & info
Research HubReference LibraryEducationCompareBlogCOAsWhy UsFAQCalculatorGlossaryWritten by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. Published research has investigated it for its selective interaction with the GHS-R1a receptor in the context of growth hormone signaling. Novo Nordisk developed it as a drug candidate, and Raun et al. concluded that its specificity made it a very interesting candidate for future clinical development. Studies noted a more selective endocrine signaling profile than earlier GHRPs such as GHRP-6. Preclinical studies have examined dose-dependent growth hormone secretion patterns in animal models. Research on Ipamorelin has proven important for investigating growth hormone (GH) regulation, given its specific design.
This article explains the Ipamorelin peptide structure and its mechanism of action. It also covers what makes it a selective secretagogue compared with older GHRPs such as GHRP-6, and what the preclinical literature actually shows. Ipamorelin is a research compound and is not characterized for human use here.
Ipamorelin is a small synthetic peptide, and its position in the field can best be understood when compared to the previous compounds. Growth hormone-releasing peptides were first described by Bowers et al. in 1980.[7] Their 1984 publication reported that a new synthetic hexapeptide, called GHRP-6, could release GH from the pituitary gland.[1] It did so via an unidentified mechanism independent of GHRH.
GHRP-6 was potent but not a clean probe of the GH axis. Bowers et al. reported GH release without any concomitant rise in LH, FSH, TSH or PRL. They did not report ACTH or cortisol. Later work in conscious swine showed that GHRP-6 also raised plasma ACTH and cortisol (Raun et al.).[2]
Ipamorelin was identified in a chemistry program screening compounds that lacked the central Ala-Trp dipeptide of GHRP-1. Its failure to raise ACTH and cortisol was an unexpected finding rather than a designed outcome. According to Raun et al.'s 1998 work, it was nonetheless the first example of a selective growth hormone secretagogue of this kind.[2]
The Ipamorelin peptide structure is a pentapeptide, written as Aib-His-D-2-Nal-D-Phe-Lys-NH2. Aib is the non-natural residue alpha-aminoisobutyric acid, and D-2-Nal is a D-configuration naphthylalanine. The use of non-natural and D-amino acids, together with the C-terminal amide, is what gives the molecule its metabolic stability.
Its endocrine selectivity is not explained by binding a different receptor. Antagonist profiling by Raun et al. showed that ipamorelin, like GHRP-6, releases GH via the same GHRP-like receptor.[2] Those authors described the absence of an ACTH and cortisol response as very surprising rather than designed. It is a fully synthetic construct that does not correspond to any natural peptide sequence.
The mode of action of Ipamorelin involves a distinct pathway and receptor compared to the GHRH receptor. This receptor, the GHS-R1a, was first discovered by Howard et al. in 1996.[3] It was found to function as a pituitary and hypothalamic receptor in regulating growth hormone release, though its endogenous ligand had not yet been identified.
It was not until 1999 that Kojima et al. discovered ghrelin, the acylated peptide.[4] That discovery led to the identification of GHS-R1a as the ghrelin receptor, thereby classifying the GHRPs as ghrelin agonists or analogs.
Ipamorelin binds GHS-R1a receptors in the somatotrophs of the pituitary gland, where it acts to induce GH secretion by activating the signal transduction pathways. It does so without using the cAMP-dependent mechanism employed by GHRH-class secretagogues. As both pathways are distinct yet interconnected, the two types of secretagogues are often studied together.
This is the heart of the Ipamorelin versus GHRP-6 comparison. In the same studies that established its GH-releasing potency, Raun et al. showed that Ipamorelin released GH with potency and efficacy comparable to GHRP-6.[2] Those same authors reported that in conscious swine, both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while ipamorelin produced ACTH and cortisol levels not significantly different from those following GHRH stimulation. That held even at doses more than 200-fold above its ED50 for GH release.
This is precisely what has made this compound selective. It acts on the GH axis via GHS-R1a, without the ACTH and cortisol rise that GHRP-6 and GHRP-2 produced in the same study. In that study none of the secretagogues tested, ipamorelin included, altered FSH, LH, PRL or TSH. For anyone studying GH biology, a probe that moves GH without simultaneously moving cortisol is a cleaner instrument. That selectivity is the single most cited feature of the molecule.
The Ipamorelin preclinical studies are where the body of evidence sits. The foundational animal pharmacology study by Raun et al. characterized GH release in rat pituitary cells in vitro, in anesthetized rats and in conscious swine.[2] The hormone-specificity work that defines the compound, including the ACTH and cortisol measurements, was carried out only in the swine.
In addition to being studied for its fundamental characteristics, the peptide has served as a research tool in specific physiological models. Andersen et al. reported in 2001 that in adult rats, Ipamorelin counteracted a glucocorticoid-induced decrease in bone formation.[5] That study examined the GH axis in the context of corticosteroid effects on bone.
Separately, Venkova et al. used Ipamorelin as a ghrelin mimetic in a rat model of postoperative ileus in 2009.[6] They reported that a single dose shortened the time to first bowel movement. That single dose did not change cumulative fecal output, food intake, or weight gain, while repeated dosing increased all three.
Together, these illustrate how the molecule has been deployed across distinct preclinical questions, all in animal or cellular systems. None predicts an outcome in people.
What the preclinical research shows
Raun et al. [2]
Rat pituitary cells in vitro, in anesthetized rats and in conscious swine
The hormone-specificity work that defines the compound, including the ACTH and cortisol measurements, was carried out only in the swine.
Original developerSingle unreplicated developer studyVenkova et al. [6]
Venkova et al. used Ipamorelin as a ghrelin mimetic in a rat model of postoperative ileus in 2009.
Rat modelHuman research on Ipamorelin is minimal and should be read as separate from the animal work. Three published studies have given it to people. An early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers characterized how the peptide behaves in the body. It also characterized its GH response across five infusion rates.[8]
Ipamorelin was then taken into clinical development for postoperative ileus, in a phase 2, multicenter, randomized, double-blind, placebo-controlled trial (NCT00672074) in 114 bowel-resection patients. Its authors reported the peptide as well tolerated, and it was no better than placebo on the key efficacy endpoint. That endpoint was median time to tolerating a standardized solid meal (25.3 h vs 32.6 h, p = 0.15). It was also no better than placebo on the secondary efficacy analyses.[9] FDA's 2024 review of the same trial gives a fuller safety picture. Serious adverse events occurred in 10 of 56 patients given ipamorelin and 9 of 58 given placebo. Two patients given ipamorelin died after colon cancer surgery complicated by a leak where the bowel was rejoined, and FDA states it is unclear whether the deaths were related to ipamorelin. Low blood potassium and high blood glucose were also more frequent on ipamorelin.[11]
The third is a 2015 anti-doping laboratory study. One volunteer was given ipamorelin intranasally, and its breakdown products were tracked in urine for two days so that doping tests could detect it.[10]
There is no approved use, and almost everything else known about the compound comes from preclinical pharmacology. Any extrapolation from this limited human data to a real-world outcome is unsupported.
Human research on Ipamorelin
Postoperative ileus [9]
114 bowel-resection patients
It was also no better than placebo on the secondary efficacy analyses.
No better than placebo on the key efficacy endpointDouble-blindFDA's 2024 review [11]
the same trial
Two patients given ipamorelin died after colon cancer surgery complicated by a leak where the bowel was rejoined.
Unclear whether the deaths were related to ipamorelinStudies on Ipamorelin have several limitations to consider when interpreting the results. There is no approved use, and the compound is not characterized for human use. Much of the defining preclinical work comes from the original developer, which raises the usual question of independent replication. The long-term effects of GHS-R1a receptor stimulation are not well characterized.
As with any research peptide, the identity and purity of the material vary across sources, which matters for any laboratory study using research-grade Ipamorelin.
Taking all this into account, the mechanism is well defined and the selectivity is its genuine distinction, though it rests on that single unreplicated developer study. The broader evidence base remains limited, and the open questions are mostly those that properly controlled studies have not yet answered.
Current limitations and open questions
Approved use
There is no approved use
the compound is not characterized for human use
Independent replication
Single unreplicated developer study
Much of the defining preclinical work comes from the original developer, which raises the usual question of independent replication.
Ipamorelin is a selective, synthetic ghrelin receptor agonist: a stable pentapeptide that acts at GHS-R1a to release growth hormone. It spares the ACTH and cortisol responses that complicated earlier GHRPs such as GHRP-6.
The preclinical pharmacology that defines it is coherent, but its selectivity rests on a single set of swine experiments from the original developer. That finding has not been independently replicated. The broader evidence base is limited, with no approved indication.
The findings describe what has been studied in preclinical systems, not what any individual should expect.
Family overviewGrowth Hormone Secretagogues Research
Three published studies have given it to people, and that human research is minimal and should be read as separate from the animal work. An early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers characterized how the peptide behaves in the body and its GH response across five infusion rates. A phase 2, multicenter, randomized, double-blind, placebo-controlled trial (NCT00672074) in 114 bowel-resection patients found it no better than placebo on the key efficacy endpoint. Its authors reported it as well tolerated, but FDA's review of the trial records two deaths among patients given ipamorelin, with their relation to the peptide unclear. A 2015 anti-doping study gave it to one volunteer intranasally and tracked its breakdown products in urine for two days. Any extrapolation from this limited human data to a real-world outcome is unsupported.
No, though both are synthetic growth hormone-releasing peptides. GHRP-6 is the synthetic hexapeptide that Bowers et al. reported in 1984, while Ipamorelin is a pentapeptide, written as Aib-His-D-2-Nal-D-Phe-Lys-NH2. Antagonist profiling by Raun et al. showed that ipamorelin, like GHRP-6, releases GH via the same GHRP-like receptor, and the difference those authors reported is endocrine selectivity. In conscious swine, both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while ipamorelin produced ACTH and cortisol levels not significantly different from those following GHRH stimulation.
No. The selectivity of Ipamorelin rests on a single set of swine experiments from the original developer, and that finding has not been independently replicated. Much of the defining preclinical work comes from that same developer, which raises the usual question of independent replication. The broader evidence base remains limited.
No. There is no approved use, and the compound is not characterized for human use. It was taken into clinical development for postoperative ileus, but the phase 2 trial found it no better than placebo on the key efficacy endpoint. Almost everything else known about the compound comes from preclinical pharmacology.
References

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
GHRP-6 was reported in 1984, its receptor found in 1996 and the body's own hormone for it in 1999. The hormone that came last reclassified the whole family.
Sermorelin held two FDA approvals, both withdrawn in 2009. What the primary regulatory record and the small human trial base actually establish.
PEG-MGF research reviewed: one PubMed record, no peer-reviewed human studies, no CAS number found, and an FDA compounding nomination withdrawn by its nominator.
An evidence-led review of tesamorelin research: what its approval covers and what it does not, and what the human trials actually found.
An evidence-led review of MGF research: what the splice variant is, its contested receptor and laboratory record, and the state of the human evidence.
An evidence-led review of IGF-1 LR3 research: weaker binding at the same receptor, what has been measured, and why the half-life claim runs backwards.
An evidence-led review of IGF-1 DES research: the same receptor as IGF-1 but different binding-protein behaviour, what has been measured, and in what.

Research use only: not for human or veterinary use. You must be 21 or over to enter.
10% off your first order
New customers · applied automatically at checkout
By entering you agree to our Terms, Research Use Only policy and Privacy Policy.
Already have an account?
You're on the list
We'll email you when there's something worth knowing about.